Table 4.

Comparison of apparently normal and clinically compromised γHV-68-infected I-A^b−/− mice that had been boosted with vacc-p79, vacc-p56, and WSN-p56

Group	Body weight (g)	Log10 virus titer		CD8+
		Spleen	Lung	p56Db+	p79Kb+
Healthy	21.0  ± 0.7*	2.2  ± 0.3*	3.1  ± 0.1*	11.9  ± 1.4*	3.9  ± 1.6
Sick	13.4  ± 1.6	2.7  ± 0.1	3.6  ± 0.2	4.5  ± 1.8†	2.8  ± 1.6†

The data were derived from I-A^b−/− mice that were infected i.p. with 5 × 10⁵ pfu of γHV-68, boosted i.p. 32 days later with 3 × 10⁷ pfu of both vacc-p79 and vacc-p56, then infected i.p. after an additional 39 days with WSN-p56. The tetramer results are for the splenic CD8⁺ set. The “healthy” mice looked clinically normal, whereas the “sick” animals were hunched and had ruffled fur. The six healthy and four sick mice were sampled at 138 (4 and 2), 151 (1 and 1), and 171 (1 and 1) days after the original γHV-68 challenge. The Pepγ assay was also used at day 151 and day 171. The percent CD8⁺ T cells staining with the p56D^b tetramer and for IFN-γ after stimulation with the p56 peptide were, respectively: Healthy, 9.9 and 8.9, 9.5 and 10.2; Sick, 7.6 and 6.4, 3.5 and 2.9. The comparable results for p79-specific CD8⁺ T cells were: Healthy, 3.5 and 1.8, 2.8 and 1.9; Sick, 5.5 and 3.2, 2.4 and 1.0. 

*Significantly different (P < 0.03) from the result for the “Sick” group. 

^† These values were no different from those for γHV-68-infected, I-A^b−/− controls, some of which were also given vacc-LCMV^b and WSN-LCMV^d. The cumulated results (% CD8⁺ in spleen) for control mice sampled (groups of two to four) at intervals from 71–139 days after the initial exposure to γHV-68 were: p56D^b+, 3.9 ± 1.7; p79K^b+, 2.2 ± 0.9. The significantly (P < 0.01) greater frequencies in healthy, boosted (vacc-p56, vacc-p79, WSN-p56) mice sampled at the same time points were: p56D^b+, 12.9 ± 3.2; p79K^b+, 5.2 ± 2.2. The results for the controls were identical to previously published data (12).